UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 144 Filer Information W

Form 144

FORM 144/A

NOTICE OF PROPOSED SALE OF SECURITIES

PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

144/A: Filer Information

Filer CIK 0001627639
Filer CCC XXXXXXXX

Previous Accession Number Of The Filing 0001968582-23-000149

Is this a LIVE or TEST Filing?

LIVE TEST

Submission Contact Information

Name

Phone

E-Mail Address

144/A: Issuer Information

Name of Issuer Sana Biotechnology, Inc

SEC File Number 001-39941

188 East Blaine St, Ste 400

Address of Issuer Seattle

WASHINGTON

98102

Phone 206-701-7914

Name of Person for Whose Account the Securities are To Be Sold FLAGSHIP VENTURES FUND V, L.P.

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer affiliate

144/A: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value			Name the Securities Exchange
common	J.P. Morgan Securities LLC 390 Madison Avenue - 6th Floor New York NY 10017	664666	4659309	191500944	05/24/2023	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144/A: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
common	05/12/201/ .	/enture Capital nvestment	Issuer			664666	05/12/2017 cas	sh

^{*} If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144/A: Securities Sold During The Past 3 Months

Nothing to Report **V**

144/A: Remarks and Signature

Remarks this filing replaces the filing made earlier on May 24, 2023. This amendment is to reflect correct amount of

shares

Date of Notice 05/24/2023

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature /s/ JPMS LLC as agent and attorney-in-fact for FLAGSHIP VENTURES FUND V, L.P.

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)